Omeros’ (OMER) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Omeros (NASDAQ:OMER) in a research note released on Wednesday, Marketbeat reports. The firm currently has a $22.00 price objective on the biopharmaceutical company’s stock.

A number of other analysts have also weighed in on OMER. Zacks Research lowered shares of Omeros from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. HC Wainwright restated a “buy” rating on shares of Omeros in a research report on Monday, July 27th. Wall Street Zen upgraded shares of Omeros from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. Finally, Weiss Ratings raised Omeros from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Three analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Omeros presently has an average rating of “Moderate Buy” and a consensus price target of $30.33.

Omeros Stock Down 13.8%

Shares of NASDAQ:OMER opened at $16.20 on Wednesday. The firm has a market cap of $1.17 billion, a P/E ratio of 6.88 and a beta of 2.57. Omeros has a 12 month low of $6.24 and a 12 month high of $21.24. The company’s 50-day moving average price is $18.41 and its two-hundred day moving average price is $13.86.

Omeros (NASDAQ:OMER) last announced its earnings results on Wednesday, August 12th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.29. The company had revenue of $28.53 million during the quarter, compared to the consensus estimate of $12.69 million. As a group, equities analysts predict that Omeros will post -0.37 earnings per share for the current fiscal year.

Insider Transactions at Omeros

In other Omeros news, VP Peter B. Cancelmo sold 25,000 shares of the company’s stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $18.54, for a total transaction of $463,500.00. Following the transaction, the vice president directly owned 200 shares in the company, valued at approximately $3,708. This represents a 99.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Arnold C. Hanish sold 10,000 shares of the company’s stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $18.95, for a total transaction of $189,500.00. Following the transaction, the director owned 5,000 shares in the company, valued at approximately $94,750. The trade was a 66.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 105,906 shares of company stock valued at $1,989,705 in the last three months. Company insiders own 10.50% of the company’s stock.

Institutional Investors Weigh In On Omeros

A number of institutional investors and hedge funds have recently modified their holdings of the business. GK Wealth Management LLC acquired a new position in Omeros in the third quarter valued at approximately $65,000. State Street Corp grew its holdings in Omeros by 20.9% during the 2nd quarter. State Street Corp now owns 2,319,906 shares of the biopharmaceutical company’s stock worth $22,062,000 after acquiring an additional 400,331 shares during the period. Engineers Gate Manager LP acquired a new stake in Omeros during the 2nd quarter worth $138,000. Squarepoint Ops LLC acquired a new stake in Omeros during the 2nd quarter worth $523,000. Finally, Arizona State Retirement System bought a new stake in shares of Omeros during the 2nd quarter valued at $179,000. 48.79% of the stock is owned by institutional investors.

Trending Headlines about Omeros

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: Cantor Fitzgerald maintained an “Overweight” rating on Omeros, suggesting the analyst sees potential value despite the European setback. Omeros Earns Overweight Rating from Cantor Fitzgerald
• Neutral Sentiment: The European Medicines Agency’s CHMP issued its opinion following a re-examination of Omeros’ original application decision. The opinion is an important regulatory step, but the formal European marketing authorization process may still involve additional review. European Medicines Agency Upholds Negative Opinion
• Negative Sentiment: The CHMP upheld its negative opinion on narsoplimab after re-examination, marking a second rejection of Omeros’ European marketing authorization application. The decision substantially weakens near-term commercialization prospects for the drug in Europe and raises concerns about the company’s ability to generate future revenue from its lead product. Omeros Receives CHMP Negative Opinion Narsoplimab Application Rejected Again
• Negative Sentiment: Omeros’ compassionate-use program for narsoplimab in Europe is also ending, further limiting patient access and potential near-term commercial activity. The stock fell below a closely watched technical support level, adding to selling pressure. Omeros Stock Sinks on Negative EU Opinion

Omeros Company Profile

Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994.

Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.